Sign In
Buy PRLD
$3.66
+0.160 (+4.57%)
At Close: Jun 03, 2026
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
09:05am, Thursday, 09'th Feb 2023
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will parti
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
01:25pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
10:32am, Wednesday, 10'th Aug 2022
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
02:31pm, Friday, 29'th Jul 2022 Benzinga
Upgrades
For The Carlyle Group Inc (NASDAQ:CG), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Carlyle Group earned $1.17 in the second quarter, compared to $0.88 in the ye
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
01:55pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 169.5% in Prelude Therapeutics Incorporated (PRLD). While the effectiveness of this highly sought-after metric
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
11:35am, Wednesday, 22'nd Jun 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 169.5% in Prelude Therapeutics Incorporated (PRLD). While the effectiveness of this highly sought-after metric
Prelude Therapeutics Reports Full Year 2021 Financial Results
11:30am, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
03:16pm, Tuesday, 15'th Mar 2022 Benzinga
Upgrades
For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
01:00pm, Friday, 11'th Mar 2022 GlobeNewswire Inc.
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Offi
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
08:00am, Friday, 11'th Mar 2022
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Office
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
01:05pm, Wednesday, 09'th Mar 2022 GlobeNewswire Inc.
Announces strategic prioritization within lead programs targeting PRMT5 and MCL1
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
03:27pm, Monday, 28'th Feb 2022 Benzinga
Upgrades
According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared to $0.69 from the ye
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
12:00pm, Friday, 11'th Feb 2022 GlobeNewswire Inc.
WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Offic
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
07:00am, Friday, 11'th Feb 2022
WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer
